Navigation Links
Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
Date:9/10/2008

Company to hold Conference Call Thursday, September 11 at 11:00 AM ET

WAYNE, Pa., Sept. 10 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that it has appointed Dr. David Ginsberg, Chief Executive Officer of Encorium Group, Inc. Dr. Ginsberg assumes the position from Dr. Kai Lindevall, who was named to the newly created role of Executive Chairman. In addition to assuming overall management of the Company and its European operations, Dr. Ginsberg will assume responsibility of North American Operations from Dr. Kenneth M. Borow, who is no longer an employee of the Company.

"The appointment of David as the Company's President and Chief Executive Officer is an exciting and positive step forward for Encorium," commented Dr. Lindevall. "David's substantial experience and knowledge of the clinical research industry will be invaluable to the expansion of the Company's core business. The addition of David to the senior management team will also allow me to focus more intently on the Company's strategic growth plan."

Dr. Ginsberg, 60, brings to Encorium over 25 years of executive experience within the biopharmaceutical industry. Most recently he was the Vice President of Medical Affairs and Clinical Affairs for KV Pharmaceuticals, a NYSE specialty pharmaceutical company that develops, manufactures, acquires and markets technology-differentiated branded products and prescription pharmaceuticals. Previously he was the Chief Medical Officer and Senior Vice President of Omnicare Clinical Research, a leading Phase I to IV co
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Billerica, Massachusetts (PRWEB) November 24, 2014 ... Simplify Panels ” from METTLER TOLEDO demonstrates how ... panel. , Power analytics and sample panel design ... control cycle chemistry and protect against corrosion and ... take up a significant amount of panel space. ...
(Date:11/23/2014)... 2014 Apiscent Labs, a privately ... chemical ingredients to the global pharmaceutical and flavor ... new website, Apiscent.com. , The Apiscent.com homepage welcomes ... design, easy navigation, rotating images and content focused ... out. , The company’s work in ...
(Date:11/22/2014)... Prominent academics, leaders of the biopharmaceutical ... 3rd at Genetic Rx, a networking conference of ... place at the Joseph B. Martin Conference Center ... present and future of genetic medicines—including siRNA, ASOs, ... well as the treatment of patients with rare ...
(Date:11/22/2014)... IL (PRWEB) November 21, 2014 On ... competitors at the 2014 Emerging Medical Technologies Summit in ... Innovator Awards. Widely regarded among Silicon Valley investors ... medical device innovation, the win also positions Briteseed ... MedTech Innovator competition in 2015 and compete with other ...
Breaking Biology Technology:New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... MA - In work that could jumpstart the promising field ... body to treat a variety of diseases and tissue defects, ... that could solve one of the key challenges associated with ... transplantation. In the work, reported in the journal ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... has published results from the North American Phase 3 trial ... fidaxomicin as a treatment for patients with Clostridium difficile ... significantly reduced recurrence rates and increased global cure rates when ...
... ST. LOUIS, Feb. 2, 2011 Sigma Life Science, the ... SIAL ), today announced that its SAGE Labs initiative ... genomes for six of the most widely used strains of ... generate and analyze sequence data using next generation sequencing systems, ...
Cached Biology Technology:Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 2The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 3The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 4The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 5The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 6Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 2Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 3Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 4
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
(Date:11/7/2014)... 6, 2014 Leading Biometric companies aim ... security revolutionizing online transactions.  Companies in focus today are: NXT-ID, ... BABA ), Google Inc. (NASDAQ: GOOG ... (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: MA) ... NXTDW), a biometric authentication company focused on the growing mobile ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3
... A tiny, fast switch that uses water droplets to create ... mechanism found in palm beetles. , The new beetle-inspired ... on the scale of a micron -- a millionth of ... larger applications like powerful adhesive bonding. Like the transistor, whose ...
... that the brains of alcoholics are smaller, lighter ... speakers at the October 2004 Congress for the ... Mannheim, Germany reviewed what is known about the ... shrinkage. Proceedings are published in the June issue ...
... and Infectious Diseases (NIAID), part of the National Institutes ... which cause such serious diseases as West Nile fever, ... defenses in different ways depending on whether they are ... to new approaches to developing vaccines and treatments against ...
Cached Biology News:Beetle-inspired switch uses water for bonding 2Investigating 'brain shrinkage' in alcoholics 2Investigating 'brain shrinkage' in alcoholics 3Investigating 'brain shrinkage' in alcoholics 4Investigating 'brain shrinkage' in alcoholics 5Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 2Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 3
... These versatile vacuum cups provide flexible ... curved, or irregular surfaces. ,PFG: Flat ... Bellows cup ,PCG: Multiple Bellows cup ... from 25 to 200 mm , ...
XA7 B6...
... linear motor and ballscrew technologies, ... Cartesian solutions that include all ... and motors., , XY ... through high-flex cabling for power, ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
Biology Products: